Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity

Current Pharmaceutical Design

Volumn 19, Issue 1, 2013, Pages 67-75

  Satoh, Hiroshi ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Helicobacter pylori; Indomethacin; Lansoprazole; NSAID; Omeprazole; Proton pump inhibitor; Small intestinal ulcer

Indexed keywords

2 [(2 PYRIDYLMETHYL)SULFINYL] 1H BENZIMIDAZOLE; ACETYLSALICYLIC ACID; AG 2000; BENZIMIDAZOLE DERIVATIVE; BISMUTH CITRATE; CIMETIDINE; EPIRIZOLE; FAMOTIDINE; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; STOMACH SECRETION INHIBITOR; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIULCER ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DUODENUM ULCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL MUCOSA PROTECTION; HELICOBACTER INFECTION; HUMAN; INTESTINE ULCER; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; PROTECTION; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID SECRETION; STOMACH ULCER; ZOLLINGER ELLISON SYNDROME;

EID: 84873968183     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811306010067     Document Type: Review

References (60)

1. Barradell LB, Faulds D, McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44: 225-50.
2. Garnett WR. Lansoprazole: a proton pump inhibitor. Ann Pharmacother 1996; 30: 1425-36.
3. Zimmermann AE, Katona BG. Lansoprazole: a comprehensive review. Pharmacotherapy 1997; 17: 308-26.
4. Murakami I, Satoh H, Asano S, Maeda R. Role of capsaicinsensitive sensory neurons and nitric oxide in the protective effect of lansoprazole, a proton pump inhibitor, on the gastric mucosa in rats. Jpn J Pharmacol 1996; 72: 137-47.
5. Blandizzi C, Natale G, Gherardi G, et al. Acid-independent gastroprotective effects of lansoprazole in experimental mucosal injury. Dig Dis Sci 1999; 44: 2039-50.
6. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000; 14 (suppl. 1): 74-81.
7. Kedika RR, Souza RF. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 2009; 54: 2312-7.
8. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991; 35: 490-6.
9. Graham DY, Opekum AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55-9.
10. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172-8.
11. Fortun PJ, Hawkey CJ. Nonsteroidal anti-inflammatory drugs and the small intestine. Curr Opin Gastroent 2007; 23: 134-41
12. Matsumoto T, Kudo T, Esaki M, et al. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by doublebaloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol 2008, 43, 490-6.
13. Satoh H, Takeuchi K. Management of NSAID/aspirin-induced small intestinal damage by GI-sparing NSAIDs, anti-ulcer drugs and food constituents. Curr Med Chem 2012; 19, 82-9.
14. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-22.
15. Kuroda M, Yoshida N, Ichikawa H, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med 2006; 17: 89-93.
16. Pozzoli C, Menozzi A, Grandi D, et al. Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine. Naunyn-Schmiedberg's Arch Pharmacol 2007; 374: 283-91.
17. Higuchi K, Yoda Y, Amagase K, et al. Prevention of NSAIDinduced small intestinal mucosal injury: prophylactic potential of lansoprazole. J Clin Biochem Nutr 2009; 45: 125-30.
18. Yoda Y, Amagase K, Kato S, et al. Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of heme oxygenase-1. J Physiol Pharmacol 2010; 61: 287-94.
19. Kanno M, Narumi S, Hirata T, et al. Inhibition of the gastric secretion in the rat by thioacetamide derivatives. J Takeda Res Labs 1973; 32: 181-7.
20. Kanno M, Narumi S, Hirata T, Gomaibashi K. Inhibitory effects of 2-quinoline thioacetamide (AG-48) on the gastric secretion and the formation of gastric ulcers. J Takeda Res Labs 1973; 32: 188-203
21. Kanai Y, Nohara A, Honda H, Kanno M, Sanno Y. inventors, Takeda Chemical Ind. Ltd., assignee. Process for producing thioamide derivatives. Japanese patent application, 1969 July (Japanese Patent Notification 47-41902, 1972).
22. Sjöstrand SE, Ryberg B, Olbe L. Stimulation and inhibition of acid secretion in the isolated guinea pig gastric mucosa. Acta Physiol Scand 1978; suppl.: 181-5.
23. +)ATPase. Nature 1981; 290: 159-61.
24. Larsson H, Carlsson E, Junggren U, et al. Inhibition of gastric acid secretion by omeprazole in the dog and rat. Gastroenterology 1983; 85: 900-7.
25. Kubo K, Oda K, Kaneko T, Satoh H, Nohara A. Synthesis of 2-[(4-fluoroalkoxy-2-pyridyl) methyl]sulfinyl]-1H-benzimidazoles as antiulcer agents. Chem Pharm Bull 1990; 38: 2853-8.
26. Nohara A, Maki Y. inventors, Takeda Chemical Ind. Ltd., assignee. 2-[2-Pyridylmethylthio-(sulfinyl)-benzimidazoles. United States patent US4628098. 1986 Dec.
27. +)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther 1989; 248: 799-805.
28. Satoh H, Inatomi N, Nagaya H, et al. Antisecretory and antiulcer activitiesofanovel proton pump inhibitor AG-1749 in dogs and rats. J Pharmacol Exp Ther 1989; 248: 806-15.
29. Nagaya H, Satoh H, Maki Y. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 1990; 252: 1289-95.
30. Satoh H, Inada I, Hirata T, Maki Y. Indometacin produces gastric antral ulcers in the refed rat. Gastroenterology 1981; 81: 719-25.
31. Inatomi N, Nagaya H, Takami K, Shino A, Satoh H. Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats. Jpn J Pharmacol 1991; 55: 437-451.
32. Inada I, Satoh H. Capsaicin-sensitive sensory neurons are involved in bicarbonate secretion induced by lansoprazole, a proton pump inhibitor, in rats. Dig Dis Sci 1996; 41: 785-90.
33. Blandizzi C, Fornai M, Colucci R, et al. Lansoprazole prevents experimental gastric injury induced by non-steroidal antiinflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol 2005; 11: 4052-60.
34. Becker JC, Grosser N, Waltke C, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun. 2006; 345: 1014-21.
35. Takagi T, Naito Y, Okada H, et al. Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of NFE2-related factor 2 and oxidation of Kelch-like ECH-associating protein 1. J Pharmacol Exp Ther 2009; 331: 255-64.
36. Leandro G, Pilotto A, Franceschi M, et al. Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig Dis Sci 2001; 46: 1924-36.
37. Peura DA. Prevention of nonsteroidal anti-inflammatory drugassociated gastrointestinal symptoms and ulcer complications. Am J Med 2004; 117 Suppl 5A: 63S-71S.
38. Yeomans ND, Svedberg LE, Naesdal J. Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal antiinflammatory drug use? Int J Clin Pract 2006; 60: 1401-7.
39. Sugano K, Matsumoto Y, Itabashi T, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with longterm low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 2011; 46: 724-35.
40. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drugrelated injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am 2010; 39: 433-64.
41. Whittle BJ. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol 2004; 500: 427-39.
42. Takeuchi K, Tanaka A, Kato S, Amagase K, Satoh H. Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin Chim Acta 2010; 411: 459-66.
43. Takeuchi K, Miyazawa T, Tanaka A, Kato S, Kunikata T. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion 2002; 66: 30-41.
44. Satoh H, Guth PH, Grossman MI. Role of food in gastrointestinal ulceration produced by indomethacin in the rat. Gastroenterology 1982; 83: 210-5.
45. Satoh H, Shiotani S, Otsuka N, Hatao K, Nishimura S. Role of dietary fibres, intestinal motility and leukotrienes in the pathogenesis of NSAID-induced small intestinal ulcers in cats. Gut 2009; 58: 1590-6.
46. Satoh H, Hara T, Murakawa D, Matsuura M, Takata K. Soluble dietary fiber protects against nonsteroidal anti-inflammatory druginduced damage to the small intestine in cats. Dig Dis Sci 2010; 55: 1264-71.
47. Satoh H. Role of dietary fiber in formation and prevention of small intestinal ulcers induced by nonsteroidal anti-inflammatory drug. Curr Pharm Des 2010; 16: 1209-13.
48. Robert A, Asano T. Resistance of germfree rats to indomethacininduced intestinal lesions. Prostaglandins 1977; 14: 333-41.
49. Scarpignato S. NSAID-induced intestinal damage: are luminal bacteria the therapeutic target? Gut 2008; 57: 145-148
50. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010; 8: 504-8.
51. Ichikawa H, Yoshida N, Takagi T, et al. Lansoprazole ameriorates intestinal mucosal damage induced by ischemia-reperfusion in rats. World J Gastroenterol 2004; 10: 2814-7.
52. Simon WA, Sturm E, Hartmann HJ, Weser U. Hydroxyl radical scavenging reactivity of proton pump inhibitors. Biochem Pharmacol 2006; 71: 1337-1341.
53. Handa O, Yoshida N, Fujita N, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res 2006; 55: 476-80.
54. Tanigawa T, Watanabe T, Higuchi K, et al. Lansoprazole, a proton pump inhibitor, suppresses production of tumor necrosis factor-α and interleukin-1ß induced by lipopolysaccharide and Helicobacter pylori bacterial components in human monocytic cells via inhibition of activation of nuclear factor-δB and extracellular signalregulated kinase. J Clin Biochem Nutr 2009; 45: 86-92.
55. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; i: 1273-5.
56. Satoh H, Guth P, Grossman MI. Role of bacteria in gastric ulceration produced by indomethacin in the rat: Cytoprotective action of antibiotics. Gastroenterology 1983; 84: 483-9
57. Iwahi T, Satoh H. inventors, Takeda Chemical Ind. Ltd., assignee. Selective antibacterial agent against campyrobacter. United States patent US5013743 1991 May.
58. Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 1998; 3: 21-7.
59. Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. Pylori cells. Antimicrob Agents Chemother 1993; 37: 769-74.
60. Suzuki M, Nakamura M, Mori M, et al. Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J Clin Gastroenterol 1995; 20 Suppl 2: S93-6.